- Revenues from Product Sales Increased 149% to $3.5 Million -
- Gross Profit Up; Net Loss Down -
TUSTIN, Calif., May 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL)
is a vertically integrated specialty pharmaceutical company headquartered
in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin
China. Through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI),
the Company engages in the research, development, manufacture, and
marketing of diagnostic, pharmaceutical, nutritional supplement, and
cosmetic products currently in the People's Republic of China. AMDL
announced today that it had sales of approximately $3.58 million
(unaudited) for the first quarter of 2008 compared to $1.4 million for the
first quarter of 2007. It should be noted that first quarter sales are
typically the lowest of the year due to Chinese holidays, which last for
several weeks, and general industry trends. Please see AMDL's Form 10-Q for
the period ended March 31, 2008 for more information.
The First Quarter 2008 Financial Highlights (unaudited) include:
-- Gross Profit. AMDL gross profit for the three months ended March 31,
2008 increased 144% to $1,771,016, compared to $726,869 for the same
period in 2007. JPI contributed $1,769,593 to the gross profit for
the three months ended March 31, 2008, compared to $715,299 for the
same period in 2007.
-- Loss from Operations and Net Loss. AMDL consolidated net loss for the
three months ended March 31, 2008 was $1,472,196 or ($0.10) per share,
compared to a consolidated net loss of $1,385,406 or ($0.14) per share
for the same period in 2007.
Gary Dreher, CEO
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved